EVOFEM BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0168 USD | +17.96% |
|
+9.09% | -73.75% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 108.4 | 288.8 | 195.9 | 61.26 | 7.886 | 1.281 |
| Enterprise Value (EV) 1 | 111.1 | 265.2 | 232.9 | 169.2 | 76.25 | 44.65 |
| P/E ratio | -0.73 x | -3.1 x | -1.14 x | -0.24 x | -0.05 x | 1.2 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 439,199,989 x | 7,430,913 x | 468,387 x | 70,299 x |
| EV / Revenue | - | - | 522,267,253 x | 20,525,285 x | 4,528,434 x | 2,451,077 x |
| EV / EBITDA | -1.44 x | -5.05 x | -2.26 x | -1.02 x | -0.92 x | -2.57 x |
| EV / FCF | -1.01 x | -7.26 x | -2.55 x | -2.42 x | -2.01 x | -6.24 x |
| FCF Yield | -99.4% | -13.8% | -39.2% | -41.4% | -49.8% | -16% |
| Price to Book | -4.64 x | 19 x | 146 x | -0.58 x | -0.11 x | -0.02 x |
| Nbr of stocks (in thousands) | 13.8 | 25 | 43.3 | 87 | 986 | 20,011 |
| Reference price 2 | 7,856 | 11,569 | 4,519 | 704.1 | 8.000 | 0.0640 |
| Announcement Date | 3/1/19 | 3/12/20 | 3/4/21 | 3/10/22 | 4/27/23 | 3/27/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | 0.446 | 8.244 | 16.84 | 18.22 |
| EBITDA 1 | -77.38 | -52.48 | -103.2 | -165.8 | -83.11 | -17.37 |
| EBIT 1 | -77.64 | -52.74 | -103.5 | -166.8 | -84.12 | -17.85 |
| Operating Margin | - | - | -23,211.66% | -2,023.3% | -499.64% | -97.96% |
| Earnings before Tax (EBT) 1 | -125.7 | -80.03 | -142.3 | -205.2 | -76.65 | 53 |
| Net income 1 | -125.7 | -80.03 | -142.3 | -205.2 | -76.7 | 52.98 |
| Net margin | - | - | -31,907.85% | -2,488.99% | -455.53% | 290.81% |
| EPS 2 | -10,769 | -3,730 | -3,973 | -2,962 | -167.5 | 0.0535 |
| Free Cash Flow 1 | -110.4 | -36.51 | -91.36 | -69.98 | -37.99 | -7.152 |
| FCF margin | - | - | -20,483.8% | -848.8% | -225.62% | -39.26% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/1/19 | 3/12/20 | 3/4/21 | 3/10/22 | 4/27/23 | 3/27/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.712 | 3.57 | 4.251 | 6.034 | 6.371 | 5.112 | 4.839 |
| EBITDA | -43.1 | -37.13 | -28.93 | -24.17 | - | - | - |
| EBIT 1 | -43.37 | -37.42 | -28.93 | -24.42 | -18.72 | - | -3.38 |
| Operating Margin | -2,533.24% | -1,048.12% | -680.52% | -404.69% | -293.89% | - | -69.85% |
| Earnings before Tax (EBT) 1 | -74.06 | -51.55 | -31.88 | -126 | 89.52 | - | -2.114 |
| Net income 1 | -74.06 | -52.6 | -31.97 | -124.1 | 89.51 | 66 | -5.098 |
| Net margin | -4,325.99% | -1,473.42% | -752.03% | -2,056.21% | 1,404.9% | 1,291.18% | -105.35% |
| EPS 2 | -900.0 | -618.7 | -360.0 | -571.2 | 20.15 | - | -0.4400 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/3/22 | 5/10/22 | 8/12/22 | 1/6/23 | 11/14/23 | 3/27/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 2.68 | - | 37 | 108 | 68.4 | 43.4 |
| Net Cash position 1 | - | 23.6 | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.0346 x | - | -0.3589 x | -0.6512 x | -0.8225 x | -2.497 x |
| Free Cash Flow 1 | -110 | -36.5 | -91.4 | -70 | -38 | -7.15 |
| ROE (net income / shareholders' equity) | 204% | 2,073% | -1,676% | 418% | 89.5% | -79.2% |
| ROA (Net income/ Total Assets) | -1,219% | -204% | -93.6% | -137% | -155% | -62.5% |
| Assets 1 | 10.31 | 39.22 | 152.1 | 150.1 | 49.36 | -84.82 |
| Book Value Per Share 2 | -1,693 | 609.0 | 31.00 | -1,204 | -72.90 | -3.320 |
| Cash Flow per Share 2 | 96.40 | 606.0 | 1,127 | 89.20 | 2.810 | - |
| Capex 1 | 0.01 | 0.16 | 2.25 | 2.94 | 0.34 | 0 |
| Capex / Sales | - | - | 505.38% | 35.65% | 2.03% | 0.02% |
| Announcement Date | 3/1/19 | 3/12/20 | 3/4/21 | 3/10/22 | 4/27/23 | 3/27/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.0168
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| -73.75% | 929K | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- EVFM Stock
- Financials Evofem Biosciences, Inc.
